Skip to main content
Premium Trial:

Request an Annual Quote

Tekmira Animals Data Shows Drug Can Protect Against Marburg 72 Hours after Infection


Tekmira Pharmaceuticals this week announced the release of new preclinical data showing that the company's RNAi-based Marburg virus drug could prevent death in non-human primates infected with a lethal dose of the pathogen.

The animals were infected with the virus, then given 0.5 mg/kg doses of the drug — TKM-Marburg — once a day for seven days 72 hours later. All of the treated primates survived.

Previously, Tekmira and collaborators at the University of Texas Medical Branch showed that TKM-Marburg could offer complete protection from lethal Marburg infection when given 24 hours and 48 hours after exposure.

In a presentation at the 6th International Symposium of Filoviruses this week, Tekmira Chief Technology Officer Ian MacLachlan said that forthcoming studies will test TKM-Marburg's efficacy in non-human primates 96 hours after Marburg infection.

Tekmira currently has a treatment for another filovirus, Ebola, in Phase I development. As reported by Gene Silencing News, the company recently received a National Institutes of Health grant to develop a single RNAi agent against both Ebola and Marburg viruses.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.